indacaterol

Also known as QAB149, QAB-149, QAB 149, 5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one

Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD) (long-term data in patients with asthma are thus far lacking). It is delivered through a dry powder inhaler.

Chemical data

Formula: C24H28N2O3
Molecular weight: 392.5 g/mol
IUPAC name: 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one
SMILES: CCC1=C(C=C2CC(CC2=C1)NC[C@@H](C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC
InChIKey: QZZUEBNBZAPZLX-QFIPXVFZSA-N
XLogP: 3.3
Polar surface area: 81.6 Å²
H-bond donors: 4
H-bond acceptors: 4
Formal charge: 0

via PubChem

Research

630 papers

Article

3 sections

Contents

Medical uses
History
References

==Medical uses== A Cochrane review found benefit in lung function in people with COPD at least as good as that seen with twice-daily long-acting beta2-agonists. {| class="wikitable floatright" |+Receptor binding affinities (Ki) [nM] !Receptor !Ki |- |β1 |6.21 |- |β2 |7.36 |- |β3 |5.48 |}